WO1994001405A1 - Lichtaktivierbare 1-(2-nitrobenzyl)-substituierte 1,4-dihydropyridine - Google Patents
Lichtaktivierbare 1-(2-nitrobenzyl)-substituierte 1,4-dihydropyridine Download PDFInfo
- Publication number
- WO1994001405A1 WO1994001405A1 PCT/EP1993/001720 EP9301720W WO9401405A1 WO 1994001405 A1 WO1994001405 A1 WO 1994001405A1 EP 9301720 W EP9301720 W EP 9301720W WO 9401405 A1 WO9401405 A1 WO 9401405A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- chain
- straight
- branched alkyl
- general formula
- Prior art date
Links
- KPRUBGVPJRMMJQ-UHFFFAOYSA-N CC1=CC=CC2=NBN=C12 Chemical compound CC1=CC=CC2=NBN=C12 KPRUBGVPJRMMJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Definitions
- the present invention relates to light-activatable l- (2-nitrobenzyl) -substituted 1,4-dihydropyridines, important intermediates for the release of highly effective 1,4-dihydropyridines, and processes for their preparation.
- the invention relates to light-activatable l- (2-nitrobenzyl) -substituted 1,4-dihydropyridines of the general formula (I)
- R 1 represents hydrogen, cyano, formyl or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by hydroxy or by straight-chain or branched alkoxy or aminoalkoxy each having up to 5 carbon atoms,
- R 2 represents cyano or nitro, or represents a radical of the formula -CO 2 A
- A denotes straight-chain or branched alkyl or alkenyl each having up to 10 carbon atoms, which may optionally be up to 2 times identical or different by carboxy, straight-chain or branched alkylthio, alkoxy, alkoxycarbonyl, acyl or acyloxy each having up to 8 carbon atoms, phenyl, phenoxy , Carboxy, hydroxy or are substituted by the group -NR ⁇ 7 ,
- R 6 and R 7 are the same or different and are hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, phenyl or benzyl,
- R 1 and R 2 together form a lactone ring of the formula /
- R 3 stands for aryl with 6 to 10 carbon atoms or for a 5- to 7-membered unsaturated heterocycle with up to 2 heteroatoms from the series S, N or O, which may be up to 3 times the same or different Halogen, nitro, trifluoromethyl, trifluoromethoxy, cyano, difluoromethoxy, straight-chain or branched alkyl, alkoxy or alkylthio each having up to 8 carbon atoms, benzyl, benzylthio, benzyloxy or phenoxy are substituted, or
- R 3 represents a radical of the formula
- B represents an oxygen or a sulfur atom
- R 4 denotes straight-chain or branched alkyl or alkenyl each having up to 10 carbon atoms, which may optionally be up to 2 times identical or different by carboxy, straight-chain or branched alkylthio, alkoxy, alkoxycarbonyl, acyl or acyloxy each having up to 8 carbon atoms, phenyl , Phenoxy, carboxy, hydroxy or substituted by the group -NR 6 R 7 ,
- R 6 and R 7 have the meaning given above
- R 5 represents hydrogen, halogen, hydroxyl, carobxy or straight-chain or branched alkyl, alkoxy or alkoxycarbonyl each having up to 8 carbon atoms,
- the compounds according to the invention exist in stereoisomeric forms which are either like image and mirror image (enantiomers) or which are not like image and Mirror image (diastereomers) behave.
- the invention relates to both the antipodes and the racemic forms as well as the diastereomer mixtures.
- the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner (cf. EL Eliel, Stereochemistry of Carbon Compounds, McGraw Hill, 1962).
- Heterocycle generally represents a 5- to 7-membered, preferably 5- to 6-membered, unsaturated ring which can contain up to 2 oxygen, sulfur and / or nitrogen atoms as heteroatoms.
- 5- and 6-membered rings with one oxygen, sulfur and or up to 2 nitrogen atoms are preferred.
- the following are preferably mentioned: thienyl, furyl, pyrrolyl, pyridyl or pyrimidyl.
- R 1 represents hydrogen, cyano, formyl or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by hydroxy or by straight-chain or branched alkoxy or aminoalkoxy each having up to 4 carbon atoms,
- R 2 represents cyano or nitro, or represents a radical of the formula -CO 2 -A,
- A means straight-chain or branched alkyl having up to 8 carbon atoms, optionally by straight-chain or branched
- R 6 and R 7 are the same or different and are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, phenyl or benzyl,
- R 1 and R 2 together form a lactone ring of the formula
- R 3 represents phenyl, naphthyl, o-pyridyl, m-pyridyl, p-pyridyl or thienyl, which may be up to 2 times identical or different by fluorine, chlorine, bromine, nitro, trifluoromethyl, trifluoromethoxy, straight-chain or branched Alkyl or alkoxy each having up to 6 carbon atoms, benzyl, benzylthio, benzyloxy or phenoxy are substituted, or
- R 3 represents a radical of the formula
- B represents an oxygen or a sulfur atom
- R 4 represents straight-chain or branched alkyl having up to 8 carbon atoms, which may optionally be straight-chain or branched alkoxy, alkylthio, alkoxycarbonyl, acyl or acyloxy each having up to 6 carbon atoms, phenyl, phenoxy, carboxy or hydroxy or by the group - NR 6 R 7 is substituted, wonn
- R 6 and R 7 have the meaning given above
- R 5 represents hydrogen, fluorine, chlorine, bromine, hydroxyl, carboxy or straight-chain or branched alkyl, alkoxy or alkoxycarbonyl each having up to 6 carbon atoms
- R 1 represents hydrogen, cyano, formyl, or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl or by straight-chain or branched alkoxy or aminoalkoxy each having up to 3 carbon atoms,
- R 2 represents cyano or nitro, or represents a radical of the formula -CO 2 A
- A denotes straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by straight-chain or branched alkoxy, alkylthio, alkoxycarbonyl or acyl each having up to 4 carbon atoms, phenyl or phenoxy,
- R 1 and R 2 together form a lactone ring of the formula
- R 3 represents phenyl, naphthyl, m-pyridyl or thienyl, which are optionally up to two times the same or different by fluorine, chlorine, nitro, trifluoromethyl, trifluoromethoxy, straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms, benzyl, Benzylthio, Benzyloxy or Phenoxy are substituted, or
- B represents an oxygen or a sulfur atom
- R 4 represents straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by straight-chain or branched alkoxy, alkylthio, alkoxycarbonyl or acyl, each having up to 4 carbon atoms, phenyl or phenoxy,
- R 5 represents hydrogen, fluorine, chlorine, bromine, hydroxyl, carboxy, or straight-chain or branched alkyl, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms,
- R 3 has the meaning given above
- R 1 , R 2 and R 4 have the meaning given above,
- R 3 - CH C - CO 2 R 4
- R 3 and R 4 have the meaning given above
- R 1 , R 2 and R 5 have the meaning given above,
- R 4 and R 5 have the meaning given above
- R 1 , R 2 and R 3 have the meaning given above,
- R 1 , R 2 , R 3 and R 4 have the meaning given above,
- R 5 has the meaning given above and
- D represents halogen or a typical leaving group, preferably tosylate or mesylate,
- Solvents for the processes [A], [B] and [C] according to the invention can here be inert organic solvents which do not change under the reaction conditions.
- These preferably include ethers such as, for example, diethyl ether, dioxane, tetrahydrofuran, glycol mono- or dimethyl ether, halogenated hydrocarbons such as di-, tri- or tetrachloimethane, dichlorethylene, trichlorethylene, ethyl acetate, toluene, acetonitrile, hexamethylphosphoric triamide, acetone and pyridine. It is of course possible to use mixtures of the solvents. Dioxane, tetrahydrofuran, dimethylformamide and pyridine are preferred.
- Suitable bases for the process [C] are generally alkali metal carbonates such as sodium or potassium carbonate, or hydrides such as sodium, potassium or calcium hydride. Sodium hydride is preferred.
- the base is generally used in an amount of 1 mol to 5 mol, preferably 1 mol to 2 mol, based in each case on 1 mol of the compounds of the general formulas (II) or (X)
- Suitable catalysts are generally p-toluenesulfonic acid, p-toluenesulfonic acid ester, sulfuric or hydrochloric acid. P-Toluenesulfonic acid is preferred.
- the auxiliaries are generally used in an amount of 1 mol to 3 mol, preferably 1 mol to 1.5 mol, in each case based on 1 mol of the compounds of the general formulas (VI) and (VIII)
- the compounds of the general formula (VII) are new and can be prepared, for example, by initially treating 2-nitrobenzylamine hydrochloride with acetoxyacetoacetic acid esters in the presence of one of the bases listed above, preferably triethylamine, in one of the solvents listed above, preferably methnaol reacted at room temperature and normal pressure, then with bases, preferably potassium carbonate, cleaves the acetoxy group and cyclized to tetranoic acid
- the compounds of the general formula (VIII) are new and can be prepared, for example, by analogy to the preparation method of the compounds of the general formula (VII), 2-nitrobenzylamines with acetoacetic acid esters, without bases, in one of the solvents listed above, preferably Methanol, at room temperature and normal pressure
- the compounds of the general formula (I) according to the invention are valuable intermediates for 1,4-dihydropyridine chemistry. Due to their light activation, in which the 2-nitrobenzyl group is split off, they enable easy access to the corresponding Ca-agonistic and Ca-antagonistic 1,4-dihydropyridines, whereby their effect is further enhanced on the one hand and also the possibility of local, tissue-specific activation of the substances by light irradiation of the lead tissue is also possible.
- the rapid activation of the compounds according to the invention in particular in the range of 1 ms, enables them to be used in a large number of cell biological, physiological and pharmacological experiments, such as, for example, light-induced competition experiments with active 1, 4-dihydropyridines in the area of individual cells or cell sections, the detection of Ca channel-mediated cell activities and the identification of Ca channels.
- a papillary muscle of approx. 1 mm in diameter and approx. 5 mm in length is prepared from a right animal and fastened in the test chamber.
- the base of the muscle is held by two metal clips, which also serve for electrical stimulation, while the other side is connected to the force transducer by a thread.
- the contractions of the muscle are recorded with a pen and simultaneously saved and evaluated with a personal computer.
- the test chamber is thermostatted (32 ° C; in In individual experiments, the temperature was reduced to 25 ° C.) Bath solution perfused at a rate of 240 ml / h.
- the solution was gassed with carbogen (95% oxygen, 5% carbon dioxide) and thus adjusted to a pH of 7.4 Substances were dissolved in pure DMSO in a concentration of 10 " 2 g ml and then gradually diluted so that a DMSO content of 0.5% was not exceeded in the bath solution when the final concentration was reached. In some experiments, the function was of the sarcoplasmic reticulum blocked by adding 10 mM caffeine to the bath solution.
- the papillary muscle is first incubated under light protection with a concentration of the starting substance that is as high as possible but still largely ineffective (typically concentrations of 0.3 to 10 ⁇ M).
- concentrations of 0.3 to 10 ⁇ M typically concentrations of 0.3 to 10 ⁇ M.
- the substances can be activated by a flash of light and the pharmacological effects of the released 1,4-dihydropyridines can be measured.
- a xenon flash lamp (output up to 350 J / flash, flash duration approx. 1 ms) was used for activation, the focus of which was suitably adjusted to the preparation.
- 1 shows the continuous contraction registrations during the triggering of a flash of light in the presence of a light-activatable Ca antagonist (example no. 2, conc. 3 ⁇ M, under 10 mM caffeine). After the flash of light is triggered, the contractions are suddenly inhibited; the exponential time constant of the contraction blocking is 300 to 500 ms.
- FIG. 9 The activation of a Ca agonist (example No. 9) is shown in FIG.
- the substance was concentrated before preparation of the papillary muscle during a Langendorff perfusion of the isolated heart of 3 ⁇ M applied over a period of 40 min. After light-induced activation of the 1,4-dihydropyridine, the contraction force increases rapidly
- the present invention also includes pharmaceutical preparations which, in addition to inert, non-toxic, pharmaceutically suitable auxiliaries and excipients, contain one or more compounds of the general formula (I) or which consist of one or more active compounds of the formula (I), and processes for the preparation of these preparations.
- the active compounds of the formula (I) should be present in these preparations in a concentration of 0.1 to 99.5% by weight, preferably 0.5 to 95% by weight, of the total mixture.
- the pharmaceutical preparations can also contain other pharmaceutical active ingredients.
- the pharmaceutical preparations listed above can be prepared in a conventional manner by known methods, for example using the auxiliary agent or excipients.
- the active ingredient (s) of the formula (I) in total amounts of about 0.01 to about 100 mg / kg, preferably in total amounts of about 1 mg / kg to 50 mg / kg body weight per 24 hours , if necessary in the form of several single doses, to achieve the desired result.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/356,410 US5606066A (en) | 1992-07-10 | 1993-07-03 | Light activable "caged" 1-(2-nitrobenzyl)-substituted 1,4-dihydropyridines |
EP93915785A EP0650477A1 (de) | 1992-07-10 | 1993-07-03 | Lichtaktivierbare 1-(2-nitrobenzyl)-substituierte 1,4-dihydropyridine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4222770.4 | 1992-07-10 | ||
DE4222770A DE4222770A1 (de) | 1992-07-10 | 1992-07-10 | Lichtaktivierbare 1-(2-Nitrobenzyl)-substituierte 1,4-Dihydropyridine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994001405A1 true WO1994001405A1 (de) | 1994-01-20 |
Family
ID=6462962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/001720 WO1994001405A1 (de) | 1992-07-10 | 1993-07-03 | Lichtaktivierbare 1-(2-nitrobenzyl)-substituierte 1,4-dihydropyridine |
Country Status (4)
Country | Link |
---|---|
US (1) | US5606066A (de) |
EP (1) | EP0650477A1 (de) |
DE (1) | DE4222770A1 (de) |
WO (1) | WO1994001405A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2447219A1 (de) * | 2010-10-28 | 2012-05-02 | Recoval Belgium | Verfahren zur Reinigung von Abwasser aus einem Verfahren zur Edelstahlschlackebehandlung |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827A1 (de) * | 1967-03-20 | 1971-03-11 | Bayer Ag | Neue Arzneimittel auf der Grundlage von 4-Aryl-1,4-dihydropyridinderivaten |
DE2949491A1 (de) * | 1978-12-18 | 1980-06-26 | Sandoz Ag | 1,4-dihydropyridine, ihre herstellung und verwendung |
EP0071819A1 (de) * | 1981-07-30 | 1983-02-16 | Bayer Ag | Dihydropyridine mit positiv inotroper Wirkung, neue Verbindungen, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung |
FR2528425A1 (fr) * | 1982-06-15 | 1983-12-16 | Bayer Ag | 1,4-dihydropyridines et composition pharmaceutique les contenant |
EP0247345A2 (de) * | 1986-04-16 | 1987-12-02 | Bristol-Myers Squibb Company | Ein Alylenaminoalkylen-heteroatom-Teil enthaltende 1,4-Dihydropyridin-3,5-dicarboxylate |
EP0255710A2 (de) * | 1986-08-04 | 1988-02-10 | The Du Pont Merck Pharmaceutical Company | Dihydropyridin-Derivate mit kalziumagonistischer und alpha-1-antagonistischer Wirkung |
EP0292161A2 (de) * | 1987-05-13 | 1988-11-23 | The Regents Of The University Of California | Lichtempfindliche Kalzium-Chelatoren |
EP0330470A2 (de) * | 1988-02-24 | 1989-08-30 | Ajinomoto Co., Inc. | Gegen Tumorzellen verwendbare 1,4-Dihydropyridin-Derivate |
-
1992
- 1992-07-10 DE DE4222770A patent/DE4222770A1/de not_active Withdrawn
-
1993
- 1993-07-03 US US08/356,410 patent/US5606066A/en not_active Expired - Fee Related
- 1993-07-03 WO PCT/EP1993/001720 patent/WO1994001405A1/de not_active Application Discontinuation
- 1993-07-03 EP EP93915785A patent/EP0650477A1/de not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827A1 (de) * | 1967-03-20 | 1971-03-11 | Bayer Ag | Neue Arzneimittel auf der Grundlage von 4-Aryl-1,4-dihydropyridinderivaten |
DE2949491A1 (de) * | 1978-12-18 | 1980-06-26 | Sandoz Ag | 1,4-dihydropyridine, ihre herstellung und verwendung |
EP0071819A1 (de) * | 1981-07-30 | 1983-02-16 | Bayer Ag | Dihydropyridine mit positiv inotroper Wirkung, neue Verbindungen, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung |
FR2528425A1 (fr) * | 1982-06-15 | 1983-12-16 | Bayer Ag | 1,4-dihydropyridines et composition pharmaceutique les contenant |
EP0247345A2 (de) * | 1986-04-16 | 1987-12-02 | Bristol-Myers Squibb Company | Ein Alylenaminoalkylen-heteroatom-Teil enthaltende 1,4-Dihydropyridin-3,5-dicarboxylate |
EP0255710A2 (de) * | 1986-08-04 | 1988-02-10 | The Du Pont Merck Pharmaceutical Company | Dihydropyridin-Derivate mit kalziumagonistischer und alpha-1-antagonistischer Wirkung |
EP0292161A2 (de) * | 1987-05-13 | 1988-11-23 | The Regents Of The University Of California | Lichtempfindliche Kalzium-Chelatoren |
EP0330470A2 (de) * | 1988-02-24 | 1989-08-30 | Ajinomoto Co., Inc. | Gegen Tumorzellen verwendbare 1,4-Dihydropyridin-Derivate |
Also Published As
Publication number | Publication date |
---|---|
DE4222770A1 (de) | 1994-01-13 |
EP0650477A1 (de) | 1995-05-03 |
US5606066A (en) | 1997-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0071819B1 (de) | Dihydropyridine mit positiv inotroper Wirkung, neue Verbindungen, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung | |
EP0088276B1 (de) | Neue Verbindungen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
EP0002208B1 (de) | Nitrosubstituierte 1,4-Dihydropyridine, diese enthaltende Arzneimittel sowie deren Herstellung | |
EP0103796B1 (de) | Neue Dihydropyrimidine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
EP0088274A1 (de) | Neue 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihrer Verwendung in Arzneimitteln | |
DE3215269A1 (de) | Durch eine heterocyklisch-aromatische gruppe n-substituierte, neuartige piperidin-, piperazin- und homopiperazin-derivate, ihr herstellungsverfahren und ihre anwendung in der therapie | |
EP0088938B1 (de) | Verwendung von Pyridinverbindungen zur Herstellung von Arzneimitteln mit antihypoxischer und Ischämie-protektiver Wirkung | |
DE3445852A1 (de) | Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln | |
EP0123112B1 (de) | Chromon- und thiochromonsubstituierte 1,4-Dihydropyridinderivate, mehrere Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
EP0209701B1 (de) | Neue 1,4-Dihydropyridine, Verfahren zur Herstellung und ihre Verwendung in Arzneimitteln | |
EP0452712A1 (de) | Neue 4-Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
EP0189045B1 (de) | Pyridopyrimidine, mehrere Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
EP0088940B1 (de) | Pyridincarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
EP0039863A1 (de) | 1,4-Dihydropyridine mit unterschiedlichen Substituenten in 2- und 6-Position, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
DE3130041A1 (de) | Dihydropyridine mit positiv inotroper wirkung, neue verbindungen, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung | |
DE2362754C2 (de) | Cyclopropylalkylaminoreste enthaltende Oxazolinverbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0234196A1 (de) | Substituierte 1,4-Dihydropyridin-3-carbonsäurepiperazide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
DE3244178A1 (de) | 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln | |
EP0179386B1 (de) | 1,4-Dihydropyridin-hydroxyamine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
EP0218068A1 (de) | Dihydropyridin-2-hydroxyamine, Verfahren zur Herstellung und ihre Verwendung in Arzneimitteln | |
EP0001108B1 (de) | Neue 1,4-Dihydropyridazine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
EP0525568A1 (de) | N-alkylierte 1,4-Dihydropyridincarbonsäureester | |
EP0650477A1 (de) | Lichtaktivierbare 1-(2-nitrobenzyl)-substituierte 1,4-dihydropyridine | |
EP0362632A2 (de) | Basische 4-Aryl-DHP-amide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
DE3501855A1 (de) | 5-aryl-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993915785 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08356410 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993915785 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993915785 Country of ref document: EP |